Heparin Forte Hasco (Heparin Sodium)

Heparin Forte Hasco is employed in clinical practice for specific anticoagulant indications where a topical route is appropriate.

• Prevention of superficial thrombophlebitis following venous catheter insertion.
• Management of small superficial clots in peripheral veins.
• Adjunct to surgical skin closure to reduce local clot formation.
• Prophylaxis of clot formation in patients with limited mobility where systemic anticoagulation is contraindicated.
• Support for hemodialysis access site maintenance to prevent clotting.
• Use in dermatologic procedures to minimize microvascular thrombosis.

The safety profile of Heparin Forte Hasco reflects the typical effects observed with cutaneous heparin products, encompassing both local skin reactions and systemic anticoagulant‑related events.

Common

• Mild skin erythema at the application site.
• Localized itching or mild rash.
• Small bruising or ecchymosis near the treated area.
• Pain or tenderness at the site.

Serious

• Development of heparin‑induced thrombocytopenia (HIT).
• Unexpected bleeding extending beyond the application site.
• Necrosis of skin tissue at the application area.
• Systemic anticoagulation leading to elevated PT/aPTT.
• Allergic reaction with hives, swelling, or difficulty breathing.
• Seizure or neurological symptoms related to intracranial hemorrhage (rare).

Clinicians should consider several precautions when prescribing Heparin Forte Hasco to ensure safe and effective use.

• Assess patient history for heparin allergy or previous HIT.
• Verify baseline platelet count and coagulation parameters before initiation.
• Avoid use on infected or severely damaged skin.
• Monitor for signs of excessive bleeding or bruising at the application site.
• Adjust or discontinue if unexpected drop in platelet count occurs.
• Use with caution in patients with renal or hepatic impairment.

Heparin Forte Hasco may interact with other agents that affect coagulation or platelet function, requiring careful management.

Avoid

• Concurrent systemic heparin or low‑molecular‑weight heparin therapy.
• Use with other injectable anticoagulants such as warfarin or direct oral anticoagulants (DOACs) without monitoring.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) or aspirin that increase bleeding risk.
• Antiplatelet agents like clopidogrel or ticagrelor.
• Thrombolytic agents such as alteplase.
• Herbal supplements with anticoagulant properties (e.g., ginkgo, garlic).
• Vitamin K antagonists (e.g., warfarin) when INR is not closely monitored.